Tailored Axillary Treatment Safely Avoids Lymph Node Removal in Breast Cancer
By Lori Solomon HealthDay Reporter
THURSDAY, March 28, 2024 -- Patients with breast cancer that has started to spread to the lymph nodes can safely avoid extensive removal of the lymph nodes with tailored axillary treatment based on response to primary systemic therapy, according to a study presented at the annual European Breast Cancer Conference, held from March 20 to 22 in Milan.
Annemiek Van Hemert, from the Netherlands Cancer Institute in Amsterdam, and colleagues examined oncological outcomes in 218 patients with pathologically proven node-positive breast cancer and more than three suspicious axillary lymph nodes who were treated according to the Marking Axillary lymph nodes with Radioactive Iodine seeds (MARI) protocol. The MARI node was excised following primary systemic therapy to tailor axillary treatment.
The researchers found that 47 percent of patients had a pathologic complete response of the MARI node and were treated with radiotherapy alone, while 53 percent of patients had residual disease of the MARI node and underwent axillary lymph node dissection plus radiotherapy. The MARI procedure had a false-negative rate of 7 percent. After a median 44 months, the axillary recurrence rate was 2.9 percent in the 103 patients who received radiation alone with no further lymph node removal. Among the 115 patients who required further lymph node removal, the axillary recurrence rate was 3.5 percent, with an overall survival rate of 90 percent and a disease-free survival rate of 82 percent.
"If we are able to predict the response based on the removal of only one lymph node, it means we can safely avoid extensive removal of the lymph nodes if no living tumor cells are left," Van Hemert said in a statement. "This will avoid serious complications, such as painful swelling in the arm, known as lymphoedema."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.